The Motley Fool··Rich SmithEli Lilly Slides Despite UBS Backing: $7B CAR-T Bet Divides Markets
Eli Lilly stock fell 2.5% after announcing a $7 billion acquisition of Kelonia Therapeutics for CAR-T cancer therapy, despite positive analyst rating.
LLYcancer treatmentGLP-1 drugs